Brief: Assembly Biosciences Announces Program Reprioritization And Organizational Update

Assembly Biosciences

20/07/2022 21:59

July 20 (Reuters) - Assembly Biosciences Inc  ASMB.O :
    * ASSEMBLY BIOSCIENCES ANNOUNCES PROGRAM REPRIORITIZATION
AND
ORGANIZATIONAL UPDATE
    * ASSEMBLY BIOSCIENCES INC - WILL RESTRUCTURE ORGANIZATION
AND
REDUCE ITS WORKFORCE
    * ASSEMBLY BIOSCIENCES INC - WILL DISCONTINUE CLINICAL
DEVELOPMENT
OF ITS FIRST-GENERATION INVESTIGATIONAL CORE INHIBITOR, VBR
    * ASSEMBLY BIOSCIENCES INC - COMPANY WORKFORCE WILL BE
REDUCED BY
APPROXIMATELY 30%, TO APPROXIMATELY 70 FULL-TIME EMPLOYEES
    * ASSEMBLY BIOSCIENCES INC - MICHAEL SAMAR, CURRENTLY CHIEF
FINANCIAL OFFICER, WILL LEAVE ORGANIZATION EFFECTIVE AUGUST 12
    * ASSEMBLY BIOSCIENCES INC - REPRIORITIZED CLINICAL PROGRAMS
AND
ORGANIZATIONAL RESTRUCTURING EXTENDS CASH RUNWAY INTO FIRST HALF
OF 2024

Source text for Eikon:  ID:nGNX1PYXHM 
Further company coverage:  ASMB.O 

 ((Reuters.Briefs@thomsonreuters.com;))